Role of topical self-assembling peptide in preventing delayed bleeding following advanced endoscopic resection: a systematic review and meta-analysis.
Self-assembling peptide (SAP) research just got another reality check. A new meta-analysis pooled data from 928 patients across 11 studies to see if SAP actually prevents delayed bleeding after advanced endoscopic resections like ESD and EMR. The expectation: SAP forms a protective gel over resection sites, reducing bleeding risk. The reality: results are basically a wash.
Surg Endosc
by Dimitrov D, Gopakumar H, Ramai D et al.
“Role of topical self-assembling peptide in preventing delayed bleeding following advanced endoscopic resection: a systematic review and meta-analysis. Dimitrov D(1)(2), Gopakumar H(1), Ramai D(3), Essilfie-Quaye K(4), Warner L(5), Almushir S(6), Dubroff J(3), Aljohani F(7), Qatomah A(1)(8), Aihara H(9). Author information: (1)Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA. (2)Department of Internal Medicine, Boston Medical Center - Brighton, Boston, MA, USA. (3)Division of Gastroenterology, Hepatology and Nutrition, University of Utah School of Medicine, Salt Lake City, UT, USA. (4)Department of Internal Medicine, HCA Florida North Florida Hospital, Gainesville, FL, USA. (5)Systematic Review Services Specialization, Academic & Research Services Librarian, University of Cincinnati, Cincinnati, OH, USA. (6)Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada. (7)Department of Medicine, Tabouk University, Tabouk, Saudi Arabia. (8)Department of Medicine , King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. (9)Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA. Haihara@bwh.harvard.edu. BACKGROUND: Delayed bleeding following endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) remains a recognized adverse event. Despite observational studies suggesting lower delayed bleeding rates with the use of self-assembling peptide (SAP), randomized data have yielded inconsistent results, precluding routine prophylactic application. We aimed to evaluate the effectiveness of SAP in preventing delayed bleeding after ESD and EMR. METHODS: We systematically searched PubMed, Embase, and the Cochrane Library through October 2025 for prospective or retrospective cohorts reporting delayed bleeding following ESD or EMR in direct association with adjunctive SAP application, with or without a comparator group. Random-effects meta-analyses estimated pooled delayed bleeding rates and, where applicable, risk ratios (RR), with prespecified subgroup analyses by resection technique. RESULTS: Eleven studies comprising 928 patients were included. Comparative analyses (five studies), SAP in conjunction with standard therapy was not associated with a reduction in delayed bleeding compared with standard care (RR 1.34, 95% CI 0.83-2.18; I2 = 0%). Findings were consistent in a sensitivity analysis restricted to randomized controlled trials (RR 1.53, 95% CI 0.85-2.76; I2 = 0%) and in a subgroup analysis of ESD-only studies (RR 1.16, 95% CI 0.65-2.08; I2 = 0%). In single-arm analyses, the pooled delayed bleeding rate following SAP application was 6.7% (95% CI 3.9-10.2%; I2 = 71.5%). Among anticoagulated patients (five studies; n = 108), the pooled bleeding rate was 11.5% (95% CI 6.3-18.0%; I2 = 0%). Procedure-specific analyses demonstrated similar bleeding rates after ESD and EMR, with substantial heterogeneity observed in EMR cohorts. CONCLUSION: Prophylactic SAP after ESD or EMR yielded delayed bleeding rates comparable to baseline, indicating no added benefit over standard practice. In anticoagulated patients, outcomes similarly matched historical benchmarks, with no evident protective effect. Further studies are required to define the patients most likely to benefit from SAP. © 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. Conflict of interest statement: Declarations. Disclosures: Hiroyuki Aihara is a consultant for Olympus America, Boston Scientific, Fujifilm, Cook Medical, Medtronic, ConMed, MicroTech, Johnson & Johnson MedTech, Swan EndoSurgical, CapsoVision, and BioDevek. Daryl Ramai is a consultant for Olympus America. Drs. Dimo Dimitrov, Harishankar Gopakumar, Abdulrahman Qatomah, Kobina Essilfie-Quaye, Lynn Warner, Sulaiman Almushir, Jason Dubroff, and Faisal Aljohani have no conflicts of interest or financial ties to disclose.”
The numbers tell the story. When SAP was added to standard care, the risk of delayed bleeding didn’t budge. The risk ratio hovered at 1.34 (confidence interval 0.83–2.18), meaning SAP worked about the same as existing protocols. Even in randomized controlled trials, the effect didn’t move the needle. In single-arm studies, delayed bleeding happened in 6.7% of cases. That’s not far off baseline rates in similar patient groups.
Researchers also drilled down into higher-risk subgroups. Among patients on anticoagulants, SAP didn’t show any unique benefit. Bleeding rates stayed in line with what’s already seen using standard methods.
Key takeaway: Self-assembling peptides are safe and feasible for topical use, but they’re not a silver bullet for post-procedure bleeding—at least not in the populations studied so far. Substantial heterogeneity in the data, especially after EMR, means there’s more to learn about who, if anyone, might get outsized benefit from SAP.
Peptide research is all about testing ideas and seeing what sticks. This meta-analysis is a solid reminder that not every peptide intervention will shift the paradigm overnight. But with new formulations and patient targeting, there’s plenty of ground left to cover. Want the full breakdown on the science? Check out the peptide research index for more context on SAP and related compounds.
The peptide field keeps moving, even when results land in the “not yet” column.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.